NCT04342429Recruiting
Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
RAD4649-19: Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 24 Mar 2020
- Start date
- 19 Mar 2020
- Primary completion date
- 27 May 2027
- Lead sponsor
- Emory University
- Diseases
- Lung cancer
- NCT number
- NCT04342429
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 19 Mar 2020 to the primary completion date, 27 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radiation therapy which would provide significant dose overlap with the planned target volume(s)
Other
- Pregnancy
Who the study is looking for
- Pathologically confirmed small cell lung cancer, limited or extensive stage.
- Patients who are offered thoracic radiotherapy with intensity-modulated proton therapy (IMPT) techniques delivering 30-66 Gy in 15-33 fractions at 2 Gy per fraction, at the recommendation of the treating radiation oncologist.
- Age 18 or greater
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Winship Cancer Institute Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.